tbuckley/cabot-search huggingface dataset:
2 The prevalence of musculoskeletal injuries, menstrual irregularity and disordered eating in junior elite athletics in the UK
Authors: J Wilkinson, L Mayhew
Journal: British Journal of Sports Medicine (2021)

The prevalence of injury in adolescent elite track and field competitors is high, 1 however only one study has been conducted with UK athletes. 2 Relative Energy Deficiency in Sport (RED-S), encapsulating the Female Athlete Triad, is a syndrome whereby decreased energy availability affects health and performance, potentially leading to an increased injury risk; particularly to bone (3). Calculating decreased energy availability is difficult, however identifying contributing factors, such as disordered eating and menstrual dysfunction, is more viable. 3 Aim This study was conducted to identify the prevalence of musculoskeletal injury, disordered eating and menstrual dysfunction in elite junior UK track and field athletes. Method Data was collected from track and field athletes ranked within the top 10 of the UK U17 rankings in 2017 or 2018, with 138 athletes participating. Participants completed a self-reported musculoskeletal injury, disordered eating and menstrual dysfunction questionnaire relating to a 12-month time period. Results This study found a 12-month retrospective injury prevalence of 43.5%. 13% of participants presented with disordered eating, whilst 37.7% of female participants presented with menstrual dysfunction. There was a statistically significant difference in injury prevalence according to gender, with more male athletes sustaining an injury compared with female athletes. No differences in injury prevalence were noted according to event group, menstrual dysfunction or disordered eating. The anatomical location displaying the highest prevalence of injury was the ankle and foot (22.5%). The anatomical structure displaying the highest 12-month injury prevalence was muscle (43.6%), followed by bone (30.9%). Additionally, 21.7% of respondents reported having previously sustained a stress fracture prior to taking part in this study. Conclusion There is a high prevalence of injuries in junior UK track and field athletes, with most injuries affecting the lower limb. Although there was no difference noted in injury risk for athletes with menstrual dysfunction or disordered eating, the prevalence of bone injuries was alarmingly high. This study indicates the requirement for future research investigating RED-S within this population. Reference Zemper, E. Track andField Injuries. In: Caine DJ, Maffulli N. (eds). Epidemiology of Pediatric Sports Injuries. Individual Sports . Med Sport Science: Volume 48. Basel, Karger; 2005. p. 138–151 D’Souza D. Track and field athletics injuries - a one-year survey. British Journal of Sports Medicine 1994; 28 (3): 197–202. Mountjoy M, Sundgot-Borgen J, Burke L, et al. The IOC consensus statement: beyond the Female Athlete Triad—Relative Energy Deficiency in Sport (RED-S). British Journal of Sports Medicine 2014; 48 : 491–497.
Abstract 15022: Using Heart Broken Index to Improve the Diagnostic Accuracy of Patient with ST elevation myocardial infarction and Shorten Door-to-Balloon Time on Emergency Room.
Authors: Ai Hsien A Li, Jung-Cheng Hsu, Kuo-Chin Chen, I-No Cheng
Journal: Circulation (2011)

Background: Door-to-balloon (D2B) time is associated with mortality in patients undergoing primary percutaneous coronary intervention for ST elevation myocardial infarction (STEMI). Any delay in do...
Novel Non-invasive Index of Myocardial-mass-at-risk Calculated from Computed Tomography Data Showed Significant Correlation with Actual Myocardial-mass-at-risk in Swine Hearts
Authors: Ide Seiko, Sumitsuji Satoru, Yokoi Kensuke, Yoshida Masatoki, Awata Masaki, Yamasaki Keita, Tachibana Koichi, Nanto Shinsuke, Sakata Yasushi
Journal: Circulation (2015)
Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial
Authors: Benjamin C. Creelan, Chao Wang, Jamie K. Teer, Eric M. Toloza, Jiqiang Yao, Sungjune Kim, Ana M. Landin, John E. Mullinax, James J. Saller, Andreas N. Saltos, David R. Noyes, Leighann B. Montoya, Wesley Curry, Shari A. Pilon-Thomas, Alberto A. Chiappori, Tawee Tanvetyanon, Frederic J. Kaye, Zachary J. Thompson, Sean J. Yoder, Bin Fang, John M. Koomen, Amod A. Sarnaik, Dung-Tsa Chen, Jose R. Conejo-Garcia, Eric B. Haura, Scott J. Antonia
Journal: Nature Medicine (2021)
Contraception in general practice before teenage pregnancy
Authors: W C Leung, K Duffield, P K Josen, E Low, K Teare, E Wray, D Churchill, J Allen, M Pringle, J Hippisley-Cox, D Ebdon, M Macpherson, S Bradley, A Mcpherson, A Macfarlane, T Foran
Journal: BMJ (2001)
Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies
Authors: Florent Malard, Béatrice Gaugler, Joel Gozlan, Lucie Bouquet, Djeneba Fofana, Lama Siblany, Deborah Eshagh, Olivier Adotevi, Caroline Laheurte, Laure Ricard, Rémy Dulery, Nicolas Stocker, Zoe van de Wyngaert, Alexis Genthon, Anne Banet, Mara Memoli, Souhila Ikhlef, Simona Sestilli, Anne Vekhof, Eolia Brissot, Zora Marjanovic, Yannick Chantran, Nancy Cuervo, Eric Ballot, Laurence Morand-Joubert, Mohamad Mohty
Journal: Blood Cancer Journal (2021)

Abstract This study evaluated the safety and immunogenicity of BNT162b2 vaccine in patients with hematological malignancies. Antibodies blocking spike binding to immobilized ACE-2 (NAb) correlated with anti-Spike (S) IgG d42 titers (Spearman r = 0.865, p &lt; 0.0001), and an anti-S IgG d42 level ≥3100 UA/mL was predictive of NAb ≥ 30%, the positivity cutoff for NAb ( p &lt; 0.0001). Only 47% of the patients achieved an anti-S IgG d42 level ≥3100 UA/mL after the two BNT162b2 inocula, compared to 87% of healthy controls. In multivariable analysis, male patients, use of B-cell targeting treatment within the last 12 months prior to vaccination, and CD19 + B-cell level &lt;120/uL, were associated with a significantly decreased probability of achieving a protective anti-S IgG level after the second BNT162b2 inoculum. Finally, using the IFN-γ ELISPOT assay, we found a significant increase in T-cell response against the S protein, with 53% of patients having an anti-S IgG-positive ELISPOT after the second BNT162b2 inoculum. There was a correlation between the anti-S ELISPOT response and IgG d42 level (Spearman r = 0.3026, p = 0.012). These findings suggest that vaccination with two BNT162b2 inocula translates into a significant increase in humoral and cellular response in patients with hematological malignancies, but only around half of the patients can likely achieve effective immune protection against COVID-19.
Moving Beyond Guidelines—Use of Value-Based Preoperative Testing
Authors: Niloofar Latifi, Deborah Grady
Journal: JAMA Internal Medicine (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Magnetization‐Switchable Implant System to Target Delivery of Stem Cell‐Loaded Bioactive Polymeric Microcarriers
Authors: Gwangjun Go, Ami Yoo, Seokjae Kim, Jong Keun Seon, Chang‐Sei Kim, Jong‐Oh Park, Eunpyo Choi
Journal: Advanced Healthcare Materials (2021)

Abstract Various magnetic microcarrier systems capable of transporting cells to target lesions are developed for therapeutic agent‐based tissue regeneration. However, the need for bioactive molecules and cells, the potential toxicity of the microcarrier, and the large volume and limited workspace of the magnetic targeting device remain challenging issues associated with microcarrier systems. Here, a multifunctional magnetic implant system is presented for targeted delivery, secure fixation, and induced differentiation of stem cells. This magnetic implant system consists of a biomaterial‐based microcarrier containing bioactive molecules, a portable magnet array device, and a biocompatible paramagnetic implant. Among biomedical applications, the magnetic implant system is developed for knee cartilage repair. The various functions of these components are verified through in vitro, phantom, and ex vivo tests. As a result, a single microcarrier can load ≈1.52 ng of transforming growth factor β (TGF‐ β 1) and 3.3 × 10 3 of stem cells and stimulate chondrogenic differentiation without extra bioactive molecule administration. Additionally, the implant system demonstrates high targeting efficiency (over 90%) of the microcarriers in a knee phantom and ex vivo pig knee joint. The results show that this implant system, which overcomes the limitations of the existing magnetic targeting system, represents an important advancement in the field.
Response to: Correspondence on “New EULAR/ACR 2019 SLE classification criteria: defining ominosity in SLE” by Pons-Estel<i>et al</i>
Authors: Laura Whittall-Garcia, Dafna D Gladman, Murray Urowitz, Jiandong Su, Zahi Touma, Sindhu R Johnson
Journal: Annals of the Rheumatic Diseases (2021)

We thank Dr Pons-Estel and colleagues1 for their interest in our2 paper proposing that a score of 20 or more in the 2019 European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) classification criteria3 4 predicts more severe disease activity in the following 5 years after the systemic lupus erythematosus (SLE) classification.2

Pons-Estel et al 1 demonstrated that 98 (15.31%) patients who were classified by 1982/1997 ACR criteria, but not classified as SLE with the 2019 EULAR/ACR classification criteria, having a score of less than 10 points, accrued less damage compared with those who had a score of ≥10.5 In our cohort of patients with SLE, only …
Activated Peripheral Blood B Cells in Rheumatoid Arthritis and Their Relationship to Anti–Tumor Necrosis Factor Treatment and Response: A Randomized Clinical Trial of the Effects of Anti–Tumor Necrosis Factor on B Cells
Authors: Nida Meednu, Jennifer Barnard, Kelly Callahan, Andreea Coca, Bethany Marston, Ralf Thiele, Darren Tabechian, Marcy Bolster, Jeffrey Curtis, Meggan Mackay, Jonathan Graf, Richard Keating, Edwin Smith, Karen Boyle, Lynette Keyes‐Elstein, Beverly Welch, Ellen Goldmuntz, Jennifer H. Anolik
Journal: Arthritis & Rheumatology (2021)

B cells can become activated in germinal center (GC) reactions in secondary lymphoid tissue and in ectopic GCs in rheumatoid arthritis (RA) synovium that may be tumor necrosis factor (TNF) and lymphotoxin (LT) dependent. This study was undertaken to characterize the peripheral B cell compartment longitudinally during anti-TNF therapy in RA.Participants were randomized in a 2:1 ratio to receive standard dosing regimens of etanercept (n = 43) or adalimumab (n = 20) for 24 weeks. Eligible participants met the American College of Rheumatology 1987 criteria for RA, had clinically active disease (Disease Activity Score in 28 joints >4.4), and were receiving stable doses of methotrexate. The primary mechanistic end point was the change in switched memory B cell fraction from baseline to week 12 in each treatment group.B cell subsets remained surprisingly stable over the course of the study regardless of treatment group, with no significant change in memory B cells. Blockade of TNF and LT with etanercept compared to blockade of TNF alone with adalimumab did not translate into significant differences in clinical response. The frequencies of multiple activated B cell populations, including CD21- double-negative memory and activated naive B cells, were higher in RA nonresponders at all time points, and CD95+ activated B cell frequencies were increased in patients receiving anti-TNF treatment in the nonresponder group. In contrast, frequencies of transitional B cells-a putative regulatory subset-were lower in the nonresponders.Overall, our results support the notion that peripheral blood B cell subsets are remarkably stable in RA and not differentially impacted by dual blockade of TNF and LT with etanercept or single blockade of TNF with adalimumab. Activated B cells do associate with a less robust response.
6 Plantar plate repair – a single centre, single procedure case series
Authors: M Bernardotto, S Hodder, R Thomas, E Barlow-Kearsley
Journal: British Journal of Sports Medicine (2021)

Aim The plantar plate (PP) is an important structure that maintains stability of the metatarsophalangeal joints 1 and is commonly injured in athletes such as sprinters and ballet dancers. However, clinical outcomes following plantar plate repair are limited due to the lack of studies and the heterogeneity of surgical procedures. 2 This retrospective case series reviews the pre- and post-operative outcomes of a single-procedure PP repair series. Methods Patients who underwent PP repair using the Arthrex Complete Plantar Plate Repair System (CPR™) were identified in a single academic hospital centre. Pre- and post-operative outcomes were compared using clinical notes, radiological evaluation and the national podiatry surgery clinical outcomes database (PASCOM-10). Parameters measured included PP rupture grading, congruence, alignment, joint stability and Manchester-Oxford Foot Questionnaire (MOXFQ) scores. Results A total of 20 patients with confirmed PP rupture underwent CPR™ procedure with a team comprising 4 surgeons. Post-operative congruence correction was achieved in 95% of patients, whereas average alignment score (range 0–4) improved from 2.7 to 0.5 and joint stability score (range 0–4) from 2.6 to 0.25. MOXFQ functional outcome scores were available for 65% of patients, showing a 42%, 53% and 42% improvement for weightbearing (W/S), pain and social interaction (SI) domains respectively. Conclusions This is the first single-centre, single procedure PP repair case series. Objective radiological and clinical measures showed good improvement in the majority of patients. Functional outcome scores were more heterogeneous and limited by incomplete data collection. Our results appear replicable with no difference between surgeons performing the same procedure. References Nery C, Coughlin M, Baumfeld D, Raduan F, Mann TS, Catena F. How to classify plantar plate injuries: parameters from history and physical examination. Rev Bras Ortop 2015; 50 (6):720–728. Elmajee M, Shen Z, A’Court J, Pillai A. A Systematic Review of Plantar Plate Repair in the Management of Lesser Metatarsophalangeal Joint Instability. The Journal of Foot &amp; Ankle Surgery 2017; 56 (6):1244–1248.
Correspondence on “SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response” by Bonelli <i>et al</i>
Authors: Caoilfhionn Marie Connolly, Darya Koenig, Srekar N Ravi, Antoine Azar, Sam Kant, Monika Dalal, Jessica Duchen, Philip Seo, Brendan Antiochos, Julie J Paik, Duvuru Geetha
Journal: Annals of the Rheumatic Diseases (2021)

SARS-CoV-2 vaccination elicited high levels of immunogenicity in immunocompetent people in the original vaccine trials1 2 though recent studies have shown blunted immunogenicity in patients with rheumatic diseases treated with lymphocyte depleting agents.3 4 B-lymphocytes have been implicated in the pathogenesis of anti-neutrophil cytoplasmic antibidy (ANCA)-associated vasculitis (AAV) and B-cell-targeted therapy with rituximab is recognised as an established induction and maintenance strategy in management.5 6 SARS-CoV-2 infection in patients with AAV has been associated with severe outcomes,7 while rituximab has been associated with worse outcomes among patients infected with SARS-CoV-2.8 9 A recent study by Bonelli et al found evidence of an ameliorated humoral response but possible inducible cellular response in five patients treated with rituximab.10 

We studied the tolerability and humoral response to the SARS-CoV-2 vaccine series in 48 patients with a diagnosis of AAV. Patients underwent SARS-CoV-2 antispike antibody testing to assess humoral response. Antibody testing was performed using antispike IgG enzyme immunoassay (Roche Elecsys via Quest, DiaSorin Liaison assay via LabCorp or Euroimmun via Hopkins lab). Demographics, clinical information including immunosuppressive therapy were extracted from medical records. Time from last rituximab administration to receipt of the first dose of the vaccine was recorded. We recorded serum creatinine, white blood cell count, serum immunoglobulins, Cluster of CD19 and …
Abstract 9139: Mitochondrial Aldehyde Dehydrogenase 2*2 Allele Carriers Possess Better Cardioprotection Results After Cardioplegic Arrest During Open-Heart Surgery
Authors: Hao Zhang, Dingxu Gong, Yujian Zhang, Shoujun Li, Fuxia Yan, Shengshou Hu
Journal: Circulation (2011)

Introduction: Previous rodent studies indicated aldehyde dehydrogenase-2 (ALDH2) activation conferred cardioprotection. About 40% East Asians carry an ALDH2*2 allele to result in a reduced ALDH2 activity. The influence of ALDH2*2 on human cardioprotection after cardioplegia has not been studied, and we hypothesized that ALDH2*2 allele could have an effect on it. Methods: A prospective cohort of East Asians with a diagnosis of Tetralogy of Fallot (n=80) undergoing elective surgical repair were genotyped. All subjects followed the same operation and ICU protocol. Myocardium samples were dissected after cardioplegic arrest and detailed clinical information were collected. Myocardium ALDH2 activity, 4-hydroxy-2-nonenal (4-HNE) adducts and glutathione (GSH) levels, and expressions of ALDH2 and activating transcription factor-4 (ATF4), a key transcriptional regulator for GSH formation, were determined by spectrophotography, ELISA, and western blotting respectively. All the experimental and clinical results were compared between ALDH2*2 carriers and non-carriers. Results: ALDH2*2 allele presented in 38.75% of the patients. Myocardium ALDH2 enzyme activity difference among ALDH2*2 carriers and non-carriers disappeared during cardioplegia. ALDH2*2 carriers expressed less ALDH2 and more ATF4, and they got lower 4-HNE adducts levels and higher GSH levels. A lower postoperative inotropic score and troponin I level, and shorter length of hospital stay were observed in ALDH2*2 carriers (Table). Conclusions: In order to antagonize oxidative stress, ALDH2*2 carriers developed a compensatory larger myocardium GSH pool through ATF4 activation. When ALDH2 activity was impaired during cardioplegia, this larger GSH pool leaded to unexpectedly better cardioprotection results on ALDH2*2 carriers. ALDH2 genotype might be served as a genetic predictor for cardioprotection, and new cardioprotective strategies for ALDH2*2 non- carriers should be developed.
Both SARS-CoV-2 infection and vaccination in pregnancy elicited neutralizing antibodies in pregnant women and newborns
Authors: Irene Cassaniti, Elena Percivalle, Paola Zelini, Kimta Ngaradoumbe Nanhorngue, Anna Parolo, Valeria Bernardi, Gianfranco Jorizzo, Peter Santer, Francesca Perotti, Arsenio Spinillo, Daniele Lilleri, Fausto Baldanti
Journal: Clinical Microbiology and Infection (2021)
TCF-1 controls Treg cell functions that regulate inflammation, CD8+ T cell cytotoxicity and severity of colon cancer
Authors: Abu Osman, Bingyu Yan, Ying Li, Kevin D. Pavelko, Jasmine Quandt, Abdulrahman Saadalla, Mahendra Pal Singh, Majid Kazemian, Fotini Gounari, Khashayarsha Khazaie
Journal: Nature Immunology (2021)
Real-World Results on Ibrutinib in Relapsed/Refractory CLL: A 21-Month Follow-up of 95 Swedish Patients Treated in a Compassionate Use Program
Authors: Maria Winqvist, Per-Ola Andersson, Anna Asklid, Karin Karlsson, Claes Karlsson, Birgitta Lauri, Jeanette Lundin, Mattias Mattsson, Stefan Norin, Anna Bergendahl Sandstedt, Lotta Hansson, Anders Österborg
Journal: Blood (2017)
Management of Life-Threatening Acid–Base Disorders
Authors: Horacio J. Adrogué, Nicolaos E. Madias
Journal: New England Journal of Medicine (1998)

Adverse Consequences of Severe AlkalemiaSevere alkalemia (blood pH greater than 7.60) can compromise cerebral and myocardial perfusion by causing arteriolar constriction, an effect that is more pronounced in respiratory than in metabolic alkalosis (Table 2).6971 Neurologic abnormalities may ensue, including headache, tetany, seizures, lethargy, delirium, and stupor. The associated reduction in the plasma concentration of ionized calcium probably contributes to these manifestations. Although it exerts a moderate positive inotropic effect on the isolated heart, alkalemia reduces the anginal threshold and predisposes the patient to refractory supraventricular and ventricular arrhythmias. This arrhythmogenic action is more pronounced in patients with . . .
Transmission of SARS-CoV-2 in the household setting: A prospective cohort study in children and adults in England
Authors: Elizabeth Miller, Pauline A. Waight, Nick J. Andrews, Kelsey McOwat, Kevin E. Brown, Katja Höschler, Samreen Ijaz, Louise Letley, Donna Haskins, Mary Sinnathamby, Hannah Cuthbertson, Bassam Hallis, Vaishnavi Parimalanathan, Simon de Lusignan, Jamie Lopez-Bernal
Journal: Journal of Infection (2021)

To measure secondary attack rates (SARs) in prospectively followed household contacts of paediatric and adult cases of SARS-CoV-2 infection in England.